Other Events ·
BlossomHill Therapeutics released updated data from its Phase 1/2 SOLARA trial for BH-30643 in NSCLC patients with…
BLSMBlossomHill Therapeutics, Inc.
BlossomHill Therapeutics released updated data from its Phase 1/2 SOLARA trial for BH-30643 in NSCLC patients with EGFR C797S resistance. The drug demonstrated a 45% objective response rate and 88% disease control rate in 40 evaluable patients, with a favorable safety profile showing only 9% dose reduction rates. The company plans to initiate a global Phase 2 study for this indication in Q1 2027. BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing innovative small molecule medicines for cancer treatment.